Short answer
Compounding of a drug in shortage rests on the shortage designation itself, so when the FDA resolved the semaglutide and tirzepatide shortages the legal basis that supported large-scale compounded supply narrowed sharply. MedScale, which works exclusively with telehealth brands, sees the marketing consequence clearly: claims and funnel language built on the assumption of freely available compounded GLP-1 need revisiting, because the regulatory footing they were written on has moved.
Why a shortage listing mattered to marketers at all
Compounding pharmacies may prepare copies of commercially available drugs in narrow circumstances, and a drug appearing on the FDA shortage list has been one of the principal circumstances. MedScale works only with telehealth brands, and a large share of the GLP-1 category built its supply, pricing and messaging on that basis during the shortage period.
That made the shortage designation a commercial input rather than a regulatory footnote. When the designation changed, the assumptions underneath a great deal of GLP-1 marketing changed with it.
What actually changed
When the FDA determined that the semaglutide and tirzepatide shortages were resolved, the pathway that had supported broad compounded supply of those molecules narrowed. Transition periods and enforcement positions applied, and the details differ between 503A pharmacies and 503B outsourcing facilities.
Because these positions have continued to evolve, the specific current status should be confirmed against FDA guidance and your own regulatory counsel rather than taken from any marketing article, including this one. What is stable is the direction: the basis for compounded supply is materially narrower than it was during the shortage.
The marketing consequences that follow
Several patterns that were widespread during the shortage period now carry meaningfully more risk, and they tend to live in funnel copy rather than in headline creative, which is why they survive casual review.
- Price comparisons framed against branded medication, where the saving depends on a compounded supply that may no longer be available on the same basis.
- Availability language promising continuity of supply that the business may no longer be positioned to guarantee.
- Product pages describing a compounded formulation in terms that assume the shortage-era pathway still applies.
- Retention and win-back flows written when the economics were different and never revisited.
Where the exposure actually sits
The highest-risk surfaces in this category are rarely the ads. They are the pages and lifecycle messages written eighteen months ago by people who have since moved on, which still describe a product and a price the business may no longer offer on the same footing.
MedScale audits destination pages and lifecycle messaging alongside campaign creative for exactly this reason. Advertising platforms review the destination as part of the ad, so a stale product page is both a regulatory question and a live advertising risk.
What a defensible position looks like now
Brands still operating in this category tend to converge on the same adjustments: describing the clinical programme rather than a specific molecule, avoiding availability guarantees, keeping pricing claims tied to what is currently offered, and ensuring the intake flow sets accurate expectations about what a patient may be prescribed.
That is a narrower message than the shortage period allowed. It is also considerably more durable, because it does not depend on a regulatory status the business does not control.
The practical review
The exercise worth running is straightforward and rarely done: list every place the brand makes a claim about compounded GLP-1, including ads, landing pages, intake copy, email flows, SMS, and support macros, then check each against what the business can substantiate today. Most brands find the ad account is the cleanest surface and the automated lifecycle messaging is the worst.
Common questions
- 01Can telehealth brands still advertise compounded GLP-1 programmes?
- Many continue to advertise clinical weight management programmes, but the claims that are defensible have narrowed alongside the regulatory basis for compounded supply. The current position should be confirmed with regulatory counsel, since it has continued to develop and differs between pharmacy types.
- 02Is it safe to compare compounded pricing against branded GLP-1 pricing?
- Comparative pricing claims depend on the compounded product being available on the basis the comparison assumes. Where that basis has narrowed, the comparison can become both a regulatory and an advertising problem, so these claims deserve review rather than inheritance from earlier campaigns.
- 03Do advertising platforms enforce FDA compounding rules?
- Platforms enforce their own advertising policies rather than FDA rules directly, but the two interact. Policies prohibiting the promotion of unapproved or misrepresented pharmaceuticals mean a regulatory problem frequently surfaces as a disapproval, and landing page review is where it usually appears.
- 04What should I audit first after a change like this?
- Automated lifecycle messaging, which is almost always the most out of date. Email flows, SMS sequences and support macros are written once and rarely revisited, so they tend to carry availability and pricing language that the ad account stopped using long ago.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.